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Metastasis, the movement of tumor cells from a primary site
to progressively colonize distant organs, is the leading cause
of cancer mortality. Emerging evidences show that tumor-
educated host microenvironment cooperates with tumor cells
during the multiple stage of metastasis, making tumor cells
evade immune attack, resistant to apoptosis, and proliferate
in distant organ (Liu et al., 2016; Quail and Joyce, 2013).
This microenvironment consists of an elaborate array of
inﬂammatory cells, ﬁbroblastic cells, blood vessels, and the
extracellular matrix (Joyce and Fearon, 2015; Liu and Cao,
2016). Re-educating the tumor-promoting microenvironment,
especially activating the disabled immune system, is proved
to be an effective strategy for treating cancer, such as
immune checkpoint blockade (Pardoll, 2012; Tan et al.,
2016). Therefore, uncovering the molecules of host
microenvironment which may promote or inhibit tumor cell
metastasis will be helpful to the design of cancer therapeutic
approaches, although challenging but desperately needed.
In recent issue of Nature, Adams and colleagues per-
formed a genome-wide in vivo screen of 810 mutant mouse
lines to identify important metastatic regulators in host
microenvironment (van der Weyden et al., 2017). This study
was based on the “Sanger Mouse Genetics Project” in their
institute to study new roles for a broad range of genes by
generating more than 900 knockout mice (White et al.,
2013). Therefore, the researchers used an “experimental
metastasis assay” by intravenous administration of mouse
metastatic melanoma cells in 810 mouse lines therein and
then assessed the pulmonary metastasis. Compared with
the wild-type mouse, they found that 15 mutant mouse lines
showed signiﬁcantly decreased pulmonary metastatic foci
and 8 mutant mouse lines increased. Notably, most of these
23 genes were immune-related, indicating a key role of the
immune system in microenvironmental regulation of metas-
tasis.
They further focused on sphingosine-1-phosphate (S1P)
transporter spinster homologue 2 (Spns2), as Spns2 mutant
mice showed the most signiﬁcant decrease in pulmonary
metastasis. Spns2 is the cell-surface transporter of S1P,
which regulates the egress of immune cells (T and B cells)
from the lymphoid organs into the lymphatic vessels
(Matloubian et al., 2004). Consistently, Spns2tm1a/tm1a mice
showed decreased S1P level in the serum, and a signiﬁcant
reduction in circulating T and B cells, but not other cell lin-
eages. In the lung of mutant mice, T and B cells were
also reduced, while NK cells were increased. Mice with
lymphatic endothelial cell (LEC)-speciﬁc deletion of Spns2
(Spns2tm1c/tm1c; Lyve1cre/+ mice) had the similar phenotype
with Spns2tm1a/tm1a mice, indicating deﬁciency in LEC Spns2
was responsible for the reduction of peripheral T and B cells.
To determine how the alternated lymphocyte distribution
could affect metastasis, intensive analysis of T cell subgroup
was conducted. Interestingly, despite of their reduction in Tcell
numbers, Spns2tm1a/tm1a mice showed an extremely higher
percentage of anti-tumoral effector T cells. And increased
production of interferon-γ (IFN-γ) and enhanced B16-F10
target cell killing was also found in CD8+ T cells from
Spns2tm1a/tm1a mice, suggesting a role of CD8+ T cells in the
suppression of metastasis. However, by in vivo antibody
depletion of CD8+ T cells, the number of metastatic foci in
mutant mice was still less than that in wild-type mice. In con-
sideration of elevated NK cells in the lung, researchers elimi-
nated NK cells in these mice, which could not restore the
pulmonary metastasis yet. Only when the mutant mice
received depletion of both CD8+ T cells and NK cells, the
number of metastatic foci showed no difference with the wild-











type mice. Therefore, both CD8+ T cells and NK cells con-
tributed to the reduced pulmonarymetastasis in Spns2tm1a/tm1a
mice.
Taking together, this impressive study by Adams and
colleagues identiﬁed several previously unknown molecules
in host microenvironment to regulate metastasis through the
powerful tool of genome-wide in vivo screen. They found
host Spns2 plays a role in promoting metastasis via modu-
lating lymphocyte trafﬁcking (Fig. 1), outlining Spns2 as a
promising therapeutic target against tumor metastasis, which
may take the place of existing S1P pathway interventions to
overcome their broad side-effect.
Immunotherapy is now proved to be quite effective in the
treatment of metastatic cancer. Polarizing the activation of
immune response in host microenvironment against tumor is
promising (Chen et al., 2014). Thus, this work based on
genome-wide in vivo screen provides a comprehensive view
of the interaction between tumors and immune system and
the regulation of the complex immune networks. In the
future, more systematic and lager scale of host genes are
needed to be included in this kind of in vivo screen. Also, the
expression proﬁling of the metastatic prone organs may be
combined with this in vivo screen approach to ﬁnd the
potential molecules involved in metastatic organisms. As to
the translation of Spns2-targeting therapy into clinical appli-
cation, there are still some questions to be further addres-
sed: How is the expression and what is the function of Spns2
in other host cells? Do the alternated B cells and CD4+ T
cells modulate metastasis in Spns2-deﬁcient mice? How
does Spns2 regulate NK cell distribution? In sum, microen-
vironmental regulation of tumor progression needs to be
extensively investigated, which may provide novel thera-
peutic strategies to control metastasis.
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Figure 1. Genome-wide in vivo screen identiﬁes host Spns2 in promoting cancer metastasis. Adams and colleagues identify
23 novel genes in host microenvironment to regulate metastasis by genome-wide in vivo screen using an experimental metastasis
assay. Host Spns2 is demonstrated as an important metastatic promoter via modulating lymphocyte trafﬁcking. CTL, cytotoxic T
lymphocyte; NK cell, natural killer cell; S1P, sphingosine-1-phosphate; Spns2, S1P transporter spinster homologue 2.
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